Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norgestrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 8/20 | 1.00 |
| ▸ | AR | P10275 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.71 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levonorgestrel SCHEMBL3916570 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL14360765 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL27597 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL691861 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Norgestrel SCHEMBL4319113 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL825664 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL22364344 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL21741985 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL20927506 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL11697371 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11834 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | claimed |
| CN-121586586-A | Process for preparing ophthalmic compositions of low solubility materials | 全福生物科技股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| EP-4679086-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20260000613-A1 | INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS | FORDOZ PHARMA CORP. (US) | 2026-01-01 | — | — | US | claimed |
| US-12485128-B2 | Progestogen-only oral contraception | Navad Life Sciences PTE, Ltd. (SG) | 2025-12-02 | — | — | US | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| EP-4637777-A1 | USE OF ESTETROL IN HEPATICALLY IMPAIRED PATIENTS | Estetra SRL (BE) | 2025-10-29 | — | — | EP | claimed |
| US-20250255968-A1 | INTRAVAGINAL DEVICES FOR DRUG DELIVERY | KISER PATRICK F (US) | 2025-08-14 | — | — | US | claimed |
| EP-3884914-B1 | AN OVERMOULDABLE SUBSTRATE AND USES THEREOF | QPHARMA AB (SE) | 2025-05-21 | — | — | EP | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
| US-4327725-A | Osmotic device with hydrogel driving member | ALZA CORPORATION (US) | 1982-05-04 | — | — | US | claimed |
| US-4310510-A | Self administrable anti-fertility composition | SHERMAN KENNETH N | 1982-01-12 | — | — | US | claimed |
| US-4252787-A | CONTRACEPTIVES, PROGESTATIONAL ACTIVITY, STEROIDS | CAMBRIDGE RESEARCH AND DEVELOPMENT GROUP (US) | 1981-02-24 | — | — | US | claimed |
| US-4237885-A | Delivery system with mated members for storing and releasing a plurality of beneficial agents | ALZA CORPORATION (US) | 1980-12-09 | — | — | US | claimed |
| US-4215691-A | Vaginal contraceptive system made from block copolymer | ALZA CORPORATION (US) | 1980-08-05 | — | — | US | claimed |
| US-3942641-A | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-03-09 | — | — | US | claimed |
| US-3932635-A | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-01-13 | — | — | US | claimed |